Intranasal formulation for osteoporosis treatment to be withdrawn; new restriction to indication for injectable use in Paget’s disease. The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that calcitonin-containing medicines should only be used for short-term treatment, because of evidence that long-term use of these medicines is associated with an increased risk of cancer.
Otros documentos
⌘K
- Recomendaciones para el diagnóstico y tratamiento de eventos trombóticos tras la vacunación frente a la COVID-19
- IOF Report_SPAIN 2018
- Ranelato de Estroncio
- European guidance for the diagnosis and management of osteoporosis in postmenopausal women
- Vitamin D supplementation in elderly or postmenopausal women
- Recomendaciones para la valoración y tratamiento de la osteoporosis primaria en mujeres
- La Agencia Europea del Medicamento recomienda limitar el uso a largo plazo de medicamentos con calcitonina
- Informe Anual RNFC 2018
- Informe Farmacovigilancia nº 5
- Inicio
- Otros documentos
- La Agencia Europea del Medicamento recomienda limitar el uso a largo plazo de medicamentos con calcitonina
